Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

Fintel reports that on November 5, 2024, William Blair initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...

Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering ...

Camp4 Therapeutics (CAMP) stock gains after J.P. Morgan and Piper Sandler launched its coverage with Overweight ...

On Tuesday, Piper Sandler began coverage of CAMP4 Therapeutics Corp (NASDAQ:CAMP) stock with an Overweight rating and a price target of $18.00. The firm highlighted CAMP4's innovative work in the ...

Tuesday, Leerink Partners initiated coverage on shares of CAMP4 Therapeutics Corp (NASDAQ: CAMP) with an Outperform rating and a price target of $17.00. The coverage is based on the potential of ...

On Tuesday, Piper Sandler began coverage of CAMP4 Therapeutics Corp (NASDAQ:CAMP) stock with an Overweight rating and a price target of $18.00. The firm highlighted CAMP4's innovative work in the ...

Tuesday, William Blair initiated coverage on CAMP4 Therapeutics Corp (NASDAQ: CAMP) shares with an Outperform rating and a fair value estimate of $27.43 per share. The firm recognized CAMP4's ...

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...

The stock of CAMP4 Therapeutics Corp (NASDAQ: CAMP) has decreased by -18.21 when compared to last closing price of 10.05. Despite this, the company has experienced a -26.01% fall in its stock price ...